Marchetti, Claudia
Marchetti, Claudia
ROMA - Dipartimento di Scienze della vita e sanità pubblica
A commentary on the discrepancy between blood and tumour BRCA testing: An open question
2022 De Paolis, Elisa; Marchetti, Claudia; Concolino, Paola; Scambia, Giovanni; Urbani, Andrea; Fagotti, Anna; Minucci, Angelo
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer
2022 Chiusolo, Patrizia; Marchetti, Claudia; Rossi, Monica; Minnella, Gessica; Salutari, Vanda; Distefano, Mariagrazia; Giammarco, Sabrina; Metafuni, Elisabetta; Minucci, Angelo; Frioni, Filippo; Gasbarrino, Cristiana; Colangelo, Maria; Orteschi, Daniela; Fagotti, Anna; Lorusso, Domenica; Pagano, Livio; De Stefano, Valerio; Scambia, Giovanni; Sica, Simona
BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score
2022 Ergasti, R.; Marchetti, C.; Tudisco, R.; Iervolino, A.; Naldini, A.; Oliva, R.; Inzani, F.; Scambia, G.; Fagotti, A.
BRCA testing on buccal swab to improve access to healthcare and cancer prevention: A performance evaluation
2022 De Paolis, E.; Perrucci, A.; Marchetti, C.; Pietragalla, A.; Scambia, G.; Urbani, A.; Fagotti, A.; Minucci, A.
Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients
2022 Buttarelli, M.; Ciucci, A.; Palluzzi, F.; Raspaglio, G.; Marchetti, C.; Perrone, E.; Minucci, A.; Giaco, L.; Fagotti, A.; Scambia, G.; Gallo, D.
Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance
2022 Palluzzi, E.; Marchetti, C.; Cappuccio, S.; Avesani, G.; Macchia, G.; Gambacorta, M. A.; Cocciolillo, F.; Scambia, G.; Fagotti, A.
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis
2022 Musacchio, L.; Valsecchi, A. A.; Salutari, V.; Valabrega, G.; Camarda, F.; Tuninetti, V.; Giannone, G.; Bartoletti, M.; Marchetti, C.; Pignata, S.; Fagotti, A.; Scambia, G.; Di Maio, M.; Lorusso, D.
Nomogram to predict feasibility of minimally invasive interval debulking surgery in advanced ovarian cancer
2022 Conte, C.; Rosati, A.; Marchetti, C.; Iacobelli, V.; Quagliozzi, L.; Gallucci, V.; Gueli Alletti, S.; Scambia, G.; Fagotti, A.
Risk reducing surgery with peritoneal staging in BRCA1-2 mutation carriers. A prospective study
2022 Marchetti, C.; Arcieri, M.; Vertechy, L.; Ergasti, R.; Russo, G.; Zannoni, G. F.; Minucci, A.; Ercoli, A.; Scambia, G.; Fagotti, A.
The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery
2022 Bizzarri, N.; Marchetti, C.; Conte, C.; Loverro, M.; Giudice, M. T.; Quagliozzi, L.; Distefano, M.; Chiantera, V.; Scambia, G.; Fagotti, A.
Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors
2022 Marchetti, Claudia; Fagotti, Anna; Scambia, Giovanni
The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer
2022 Bizzarri, Nicolò; D'Indinosante, Marco; Marchetti, Claudia; Tudisco, Riccardo; Turchiano, Francesca; Scambia, Giovanni; Fagotti, Anna
What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study
2022 Perrone, E.; Tudisco, R.; Pafundi, P. C.; Guido, D.; Ciucci, A.; Martinelli, E.; Zannoni, G. F.; Piermattei, A.; Spadola, S.; Ferrante, G.; Marchetti, C.; Scambia, G.; Fagotti, A.; Gallo, D.
Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go beyond
2021 De Felice, F.; Vertechy, L.; Giudice, E.; Ergasti, R.; Boccia, S.; Fagotti, A.; Scambia, G.; Marchetti, C.
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments
2021 Marchetti, C.; De Felice, F.; Romito, A.; Iacobelli, V.; Sassu, C. M.; Corrado, G.; Ricci, C.; Scambia, G.; Fagotti, A.
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study
2021 Cecere, S. C.; Musacchio, L.; Bartoletti, M.; Salutari, V.; Arenare, L.; Lorusso, D.; Ronzino, G.; Lauria, R.; Cormio, G.; Naglieri, E.; Scollo, P.; Marchetti, C.; Raspagliesi, F.; Greggi, S.; Cinieri, S.; Bergamini, A.; Orditura, M.; Valabrega, G.; Scambia, G.; Martinelli, F.; De Matteis, E.; Cardalesi, C.; Loizzi, V.; Perniola, G.; Carella, C.; Scandurra, G.; Giannone, G.; Pignata, S.
Medical treatment of patients with gynecologic cancer during the COVID-19 pandemic
2021 Palluzzi, Eleonora; Corrado, Giacomo; Marchetti, Claudia; Bolomini, Giulia; Vertechy, Laura; Bottoni, Carolina; Distefano, Mariagrazia; Scambia, Giovanni; Ferrandina, Gabriella
Molecular profile of brca-negative long survivor high grade serous ovarian cancer patients using a somatic multigene panel
2021 De Paolis, E.; De Bonis, M.; D'Indinosante, M.; Scambia, G.; Marchetti, C.; Urbani, A.; Fagotti, A.; Minucci, A.
Fertility preservation in patients with BRCA mutations or Lynch syndrome
2021 Corrado, G.; Marchetti, C.; Trozzi, R.; Scambia, G.; Fagotti, A.
NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
2021 Marchetti, C.; D'Indinosante, M.; Bottoni, C.; Di Ilio, C.; Di Berardino, S.; Costantini, B.; Minucci, A.; Vertechy, L.; Scambia, G.; Fagotti, A.
Data di pubblicazione | Titolo | Autore(i) | File |
---|---|---|---|
1-gen-2022 | A commentary on the discrepancy between blood and tumour BRCA testing: An open question | De Paolis, Elisa; Marchetti, Claudia; Concolino, Paola; Scambia, Giovanni; Urbani, Andrea; Fagotti, Anna; Minucci, Angelo | |
1-gen-2022 | A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer | Chiusolo, Patrizia; Marchetti, Claudia; Rossi, Monica; Minnella, Gessica; Salutari, Vanda; Distefano, Mariagrazia; Giammarco, Sabrina; Metafuni, Elisabetta; Minucci, Angelo; Frioni, Filippo; Gasbarrino, Cristiana; Colangelo, Maria; Orteschi, Daniela; Fagotti, Anna; Lorusso, Domenica; Pagano, Livio; De Stefano, Valerio; Scambia, Giovanni; Sica, Simona | |
1-gen-2022 | BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score | Ergasti, R.; Marchetti, C.; Tudisco, R.; Iervolino, A.; Naldini, A.; Oliva, R.; Inzani, F.; Scambia, G.; Fagotti, A. | |
1-gen-2022 | BRCA testing on buccal swab to improve access to healthcare and cancer prevention: A performance evaluation | De Paolis, E.; Perrucci, A.; Marchetti, C.; Pietragalla, A.; Scambia, G.; Urbani, A.; Fagotti, A.; Minucci, A. | |
1-gen-2022 | Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients | Buttarelli, M.; Ciucci, A.; Palluzzi, F.; Raspaglio, G.; Marchetti, C.; Perrone, E.; Minucci, A.; Giaco, L.; Fagotti, A.; Scambia, G.; Gallo, D. | |
1-gen-2022 | Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance | Palluzzi, E.; Marchetti, C.; Cappuccio, S.; Avesani, G.; Macchia, G.; Gambacorta, M. A.; Cocciolillo, F.; Scambia, G.; Fagotti, A. | |
1-gen-2022 | MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis | Musacchio, L.; Valsecchi, A. A.; Salutari, V.; Valabrega, G.; Camarda, F.; Tuninetti, V.; Giannone, G.; Bartoletti, M.; Marchetti, C.; Pignata, S.; Fagotti, A.; Scambia, G.; Di Maio, M.; Lorusso, D. | |
1-gen-2022 | Nomogram to predict feasibility of minimally invasive interval debulking surgery in advanced ovarian cancer | Conte, C.; Rosati, A.; Marchetti, C.; Iacobelli, V.; Quagliozzi, L.; Gallucci, V.; Gueli Alletti, S.; Scambia, G.; Fagotti, A. | |
1-gen-2022 | Risk reducing surgery with peritoneal staging in BRCA1-2 mutation carriers. A prospective study | Marchetti, C.; Arcieri, M.; Vertechy, L.; Ergasti, R.; Russo, G.; Zannoni, G. F.; Minucci, A.; Ercoli, A.; Scambia, G.; Fagotti, A. | |
1-gen-2022 | The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery | Bizzarri, N.; Marchetti, C.; Conte, C.; Loverro, M.; Giudice, M. T.; Quagliozzi, L.; Distefano, M.; Chiantera, V.; Scambia, G.; Fagotti, A. | |
1-gen-2022 | Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors | Marchetti, Claudia; Fagotti, Anna; Scambia, Giovanni | |
1-gen-2022 | The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer | Bizzarri, Nicolò; D'Indinosante, Marco; Marchetti, Claudia; Tudisco, Riccardo; Turchiano, Francesca; Scambia, Giovanni; Fagotti, Anna | |
1-gen-2022 | What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study | Perrone, E.; Tudisco, R.; Pafundi, P. C.; Guido, D.; Ciucci, A.; Martinelli, E.; Zannoni, G. F.; Piermattei, A.; Spadola, S.; Ferrante, G.; Marchetti, C.; Scambia, G.; Fagotti, A.; Gallo, D. | |
1-gen-2021 | Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go beyond | De Felice, F.; Vertechy, L.; Giudice, E.; Ergasti, R.; Boccia, S.; Fagotti, A.; Scambia, G.; Marchetti, C. | |
1-gen-2021 | Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments | Marchetti, C.; De Felice, F.; Romito, A.; Iacobelli, V.; Sassu, C. M.; Corrado, G.; Ricci, C.; Scambia, G.; Fagotti, A. | |
1-gen-2021 | Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study | Cecere, S. C.; Musacchio, L.; Bartoletti, M.; Salutari, V.; Arenare, L.; Lorusso, D.; Ronzino, G.; Lauria, R.; Cormio, G.; Naglieri, E.; Scollo, P.; Marchetti, C.; Raspagliesi, F.; Greggi, S.; Cinieri, S.; Bergamini, A.; Orditura, M.; Valabrega, G.; Scambia, G.; Martinelli, F.; De Matteis, E.; Cardalesi, C.; Loizzi, V.; Perniola, G.; Carella, C.; Scandurra, G.; Giannone, G.; Pignata, S. | |
1-gen-2021 | Medical treatment of patients with gynecologic cancer during the COVID-19 pandemic | Palluzzi, Eleonora; Corrado, Giacomo; Marchetti, Claudia; Bolomini, Giulia; Vertechy, Laura; Bottoni, Carolina; Distefano, Mariagrazia; Scambia, Giovanni; Ferrandina, Gabriella | |
1-gen-2021 | Molecular profile of brca-negative long survivor high grade serous ovarian cancer patients using a somatic multigene panel | De Paolis, E.; De Bonis, M.; D'Indinosante, M.; Scambia, G.; Marchetti, C.; Urbani, A.; Fagotti, A.; Minucci, A. | |
1-gen-2021 | Fertility preservation in patients with BRCA mutations or Lynch syndrome | Corrado, G.; Marchetti, C.; Trozzi, R.; Scambia, G.; Fagotti, A. | |
1-gen-2021 | NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer | Marchetti, C.; D'Indinosante, M.; Bottoni, C.; Di Ilio, C.; Di Berardino, S.; Costantini, B.; Minucci, A.; Vertechy, L.; Scambia, G.; Fagotti, A. |